The Biotech Finances magazine (French only) interviewed Nadine Beauger, C.E.O. of the Institute for Research in Immnulogy and Cancer – Commercialization of Research (IRCoR), to talk about operations and strategies.
She discussed the main advantages of IRICoR, the partnerships of the last few years,
and the benefits of its model.
Read the article (French only, PDF, extract from the edition of August 29, 2016)
About the Institute for Research in Immunology and Cancer — Commercialization of Research
The Institute for Research in Immunology and Cancer — Commercialization of Research (IRICoR) is a not-for-profit drug discovery and commercialization centre based at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal (UdeM). IRICoR’s main objective is to rapidly translate highly innovative scientific projects from IRIC, UdeM and various centres into high value novel therapies in oncology, immunology and related indications through strong partnerships with the private sector — thereby efficiently bridging the innovation translation gap between early stage academic research and industry. For more information